Deciphera Pharmaceuticals (NASDAQ:DCPH) Trading 8% Higher
Deciphera Pharmaceuticals (NASDAQ:DCPH) Trading 8% Higher
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) shares shot up 8% during trading on Friday . The stock traded as high as $19.08 and last traded at $19.03. 5,926 shares were traded during trading, a decline of 99% from the average session volume of 956,942 shares. The stock had previously closed at $17.62.
纳斯达克(Deciphera PharmPharmticals,Inc.)股价在周五的交易中飙升8%。该股盘中一度涨至19.08美元,最新报19.03美元。当日成交量为5,926股,较956,942股的平均成交量下降99%。该股此前收盘价为17.62美元。
Analyst Ratings Changes
分析师评级发生变化
Several equities analysts have recently weighed in on DCPH shares. Stifel Nicolaus increased their price target on Deciphera Pharmaceuticals from $11.00 to $18.00 and gave the company a "hold" rating in a report on Tuesday, September 27th. Piper Sandler increased their price target on Deciphera Pharmaceuticals from $13.00 to $18.00 in a report on Sunday, September 11th. SVB Leerink increased their price target on Deciphera Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Monday, September 12th. Cowen started coverage on Deciphera Pharmaceuticals in a report on Monday, August 29th. They set an "outperform" rating and a $25.00 price target on the stock. Finally, Cowen started coverage on Deciphera Pharmaceuticals in a report on Monday, August 29th. They set an "outperform" rating and a $25.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $18.70.
几位股票分析师最近纷纷买入大昌华嘉的股票。Stifel Nicolaus在9月27日周二的一份报告中将Deciphera PharmPharmticals的目标价从11.00美元上调至18.00美元,并给予该公司“持有”评级。派珀·桑德勒在9月11日周日的一份报告中将他们对Deciphera制药的目标价从13.00美元上调至18.00美元。SVB Leerink在9月12日周一的一份报告中将Deciphera PharmPharmticals的目标价从21.00美元上调至25.00美元,并给予该公司“跑赢大盘”的评级。考恩在8月29日星期一的一份报告中开始报道Deciphera制药公司。他们为该股设定了“跑赢大盘”的评级和25.00美元的目标价。最后,考恩在8月29日星期一的一份报告中开始报道Deciphera制药公司。他们为该股设定了“跑赢大盘”的评级和25.00美元的目标价。两名股票研究分析师对该股的评级为卖出,五名分析师给予该股持有评级,五名分析师对该股给予买入评级。根据MarketBeat的数据,该公司目前的平均评级为持有,平均目标价为18.70美元。
Deciphera Pharmaceuticals Trading Up 5.0 %
Deciphera PharmPharmticals股价上涨5.0%
The firm has a market cap of $1.24 billion, a PE ratio of -4.32 and a beta of 1.00. The stock has a 50 day simple moving average of $16.44 and a 200-day simple moving average of $12.99.
该公司的市值为12.4亿美元,市盈率为-4.32,贝塔系数为1.00。该股的50日简单移动均线切入位为16.44美元,200日简单移动均线切入位为12.99美元。
Institutional Investors Weigh In On Deciphera Pharmaceuticals
机构投资者看好Deciphera制药公司
Institutional investors have recently bought and sold shares of the business. US Bancorp DE grew its position in shares of Deciphera Pharmaceuticals by 100.6% during the second quarter. US Bancorp DE now owns 4,052 shares of the company's stock valued at $53,000 after purchasing an additional 2,032 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Deciphera Pharmaceuticals during the first quarter valued at about $57,000. Lazard Asset Management LLC purchased a new position in shares of Deciphera Pharmaceuticals during the first quarter valued at about $57,000. Denali Advisors LLC grew its position in shares of Deciphera Pharmaceuticals by 33.9% during the first quarter. Denali Advisors LLC now owns 7,900 shares of the company's stock valued at $73,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Deciphera Pharmaceuticals during the first quarter valued at about $98,000. Hedge funds and other institutional investors own 72.29% of the company's stock.
机构投资者最近买卖了该公司的股票。US Bancorp DE在第二季度将其在Deciphera PharmPharmticals的股票头寸增加了100.6%。US Bancorp DE现在拥有4052股该公司股票,价值5.3万美元,此前在上个季度又购买了2032股。合并银行在第一季度购买了Deciphera PharmPharmticals的新头寸,价值约5.7万美元。Lazard Asset Management LLC在第一季度购买了Deciphera PharmPharmticals的新头寸,价值约57,000美元。Denali Advisors LLC在第一季度将其在Deciphera PharmPharmticals的股票头寸增加了33.9%。Denali Advisors LLC现在拥有7,900股该公司股票,价值73,000美元,上个季度又购买了2,000股。最后,洛杉矶资本管理有限责任公司在第一季度购买了Deciphera制药公司的新股票,价值约9.8万美元。对冲基金和其他机构投资者持有该公司72.29%的股票。
About Deciphera Pharmaceuticals
关于Deciphera制药公司
(Get Rating)
(获取评级)
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
生物制药公司Deciphera PharmPharmticals,Inc.通过解决美国和国际上限制对现有癌症疗法反应的速度和持久性的关键耐药机制,开发改善癌症患者生命的药物。它的主要候选药物是用于治疗胃肠道间质瘤(GIST)的QINLOCK,以及用于治疗二线GIST的3期试验。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
- 免费获取StockNews.com关于Deciphera制药的研究报告(DCPH)
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat:回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 让Paychex股票为您努力工作
- 利润下降对CarMax价值主张的挑战
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Deciphera PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Deciphera制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。